The FDA has cleared a blood test developed from technology invented at WashU Medicine to aid in diagnosing Alzheimer's disease. The test, PrecivityAD2, can detect amyloid plaque biomarkers with over 90% accuracy, offering a less invasive alternative to spinal taps and brain scans.